Sun Pharma announces Organon shareholder approval for acquisition
Sun Pharmaceutical Industries · Pharmaceuticals & Biotechnology
Key highlights
- Organon & Co. stockholders approved merger making Organon a Sun Pharma subsidiary
- Transaction pending customary closing conditions including regulatory approvals
- Announcement dated July 24, 2026, following earlier update on April 27, 2026
Why it's rated notable: The filing reports Organon shareholder approval for a proposed acquisition that remains subject to closing conditions and regulatory approvals, and states no transaction value, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sun Pharmaceutical Industries
- Financial resultsMajor development· Adverse for the businessSun Pharmaceutical announces Q2 & H1 FY27 results and files Limited Review Reports
- Fundraise / allotmentNotableSun Pharma completes allotment of ₹7,816 crore NCDs via private placement
- Fundraise / allotmentNotableSun Pharma board approves NCDs up to ₹10,000 crore; independent director Doshi resigns
- Fundraise / allotmentNotableSun Pharma board to meet on 12 Oct 2026 to approve NCD issuance up to ₹15,000 Cr
- Acquisition / mergerMajor developmentSun Pharma to acquire Organon at $14.00 a share; EV $11.75 billion
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.